Cytophage Technologies Ltd.
CYTO.V
TSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -4.80% | 7.23% | |||
| Depreciation & Amortization | -51.69% | -26.65% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.71% | 0.75% | |||
| Operating Income | 8.71% | -0.75% | |||
| Income Before Tax | 7.94% | -1.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 7.94% | -1.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.94% | -1.00% | |||
| EBIT | 8.71% | -0.75% | |||
| EBITDA | 0.40% | -8.23% | |||
| EPS Basic | 17.01% | 2.00% | |||
| Normalized Basic EPS | 17.39% | 2.13% | |||
| EPS Diluted | 1.36% | 2.00% | |||
| Normalized Diluted EPS | 17.39% | 2.13% | |||
| Average Basic Shares Outstanding | 10.83% | 3.19% | |||
| Average Diluted Shares Outstanding | 10.83% | 3.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||